# A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve

> **NCT01110707** · PHASE2 · COMPLETED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 131 (actual)

## Conditions studied

- Infertility
- Ovulation Induction

## Interventions

- **DRUG:** Recombinant human follicle stimulating hormone (r-hFSH)
- **DRUG:** Recombinant human luteinizing hormone (r-hLH)

## Key facts

- **NCT ID:** NCT01110707
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01-10
- **Primary completion:** 2006-11-15
- **Final completion:** 2006-11-15
- **Target enrollment:** 131 (ACTUAL)
- **Last updated:** 2018-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01110707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01110707, "A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follicular Phase in Women With Reduced Ovarian Reserve". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01110707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*